Arcutis Biotherapeutics, Inc. (ARQT)
31.20
-1.00
(-3.11%)
USD |
NASDAQ |
Oct 23, 16:00
31.20
0.00 (0.00%)
After-Hours: 20:00
Arcutis Biotherapeutics Enterprise Value : 3.794B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 3.794B |
| October 22, 2026 | 3.919B |
| October 21, 2026 | 3.878B |
| October 20, 2026 | 3.997B |
| October 19, 2026 | 3.880B |
| October 16, 2026 | 3.495B |
| October 15, 2026 | 3.530B |
| October 14, 2026 | 3.192B |
| October 13, 2026 | 3.152B |
| October 12, 2026 | 3.168B |
| October 09, 2026 | 3.213B |
| October 08, 2026 | 2.951B |
| October 07, 2026 | 2.911B |
| October 06, 2026 | 2.879B |
| October 05, 2026 | 3.034B |
| October 02, 2026 | 3.035B |
| October 01, 2026 | 3.051B |
| September 30, 2026 | 3.195B |
| September 29, 2026 | 3.235B |
| September 28, 2026 | 3.308B |
| September 25, 2026 | 3.256B |
| September 24, 2026 | 3.175B |
| September 23, 2026 | 3.188B |
| September 22, 2026 | 3.364B |
| September 21, 2026 | 3.136B |
| Date | Value |
|---|---|
| September 18, 2026 | 3.063B |
| September 17, 2026 | 3.198B |
| September 16, 2026 | 3.158B |
| September 15, 2026 | 2.828B |
| September 14, 2026 | 2.923B |
| September 11, 2026 | 2.875B |
| September 10, 2026 | 2.812B |
| September 09, 2026 | 2.869B |
| September 08, 2026 | 2.938B |
| September 04, 2026 | 2.877B |
| September 03, 2026 | 2.847B |
| September 02, 2026 | 2.871B |
| September 01, 2026 | 2.858B |
| August 31, 2026 | 2.886B |
| August 28, 2026 | 2.862B |
| August 27, 2026 | 2.999B |
| August 26, 2026 | 3.033B |
| August 25, 2026 | 2.997B |
| August 24, 2026 | 2.987B |
| August 21, 2026 | 3.025B |
| August 20, 2026 | 3.059B |
| August 19, 2026 | 3.198B |
| August 18, 2026 | 3.208B |
| August 17, 2026 | 3.092B |
| August 14, 2026 | 3.165B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Insmed, Inc. | 19.97B |
| Emergent BioSolutions, Inc. | 766.90M |
| Exelixis, Inc. | 15.39B |
| Puma Biotechnology, Inc. | 474.07M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 15.01M |
| Revenue (Quarterly) | 129.86M |
| Total Expenses (Quarterly) | 114.85M |
| EPS Diluted (Quarterly) | 0.1104 |
| Gross Profit Margin (Quarterly) | 91.58% |
| Profit Margin (Quarterly) | 11.56% |
| Earnings Yield | 0.66% |
| Operating Earnings Yield | 0.82% |
| Normalized Earnings Yield | 0.6651 |